SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: nihil who wrote (1695)3/1/2000 10:34:00 AM
From: Mikeh  Read Replies (2) | Respond to of 1754
 
Several class action suits filed against VisX for buyers between 3/99 and 2/00. Does anyone have any past experience in participating in this type of suit?



To: nihil who wrote (1695)3/1/2000 11:31:00 AM
From: Charlie Smith  Read Replies (2) | Respond to of 1754
 
nihil:

It is dangerous for the entering firm (BOL) to initiate a price war (unless it has both a production cost advantage and a quality differential.

BOL's $1.8 billion in sales vs. VISX $300 million means BOL needs no cost or quality advantage to grab share. Assuming the products are merely equivalent means BOL can afford to finance a long fight. Question is: Will they?

Charlie


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News